Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20364359 | 0.91 | ESR2 (0.50) | MAPTESR2NR1H2MAPK1SLC34A1 | |
| SCHEMBL10313002 | 0.91 | MAPT (0.52) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL20364276 | 0.89 | ABHD6 (0.44) | MAPTESR2NR1H2MAPK1SLC34A1 | |
| SCHEMBL25147666 | 0.87 | MAPT (0.49) | MAPTESR2NR1H2MAPK1SLC34A1 | |
| SCHEMBL30332059 | 0.87 | MAPT (0.49) | MAPTESR2NR1H2MAPK1SLC34A1 | |
| SCHEMBL14135312 | 0.86 | DHFR (0.41) | MAPT | |
| SCHEMBL29421798 | 0.85 | ESR2 (0.47) | MAPTESR2NR1H2GPR119 | |
| SCHEMBL30370414 | 0.84 | MAPT (0.55) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL25153126 | 0.84 | MAPT (0.55) | MAPTESR2NR1H2MAPK1HPGDS | |
| SCHEMBL13226239 | 0.84 | ESR2 (0.63) | MAPTESR2NR1H2MAPK1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178776-A1 | DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178776-A1 | DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS | GRM5, GRIK5, GRM3 | MAPT 528/4885ESR2 1535/4885NR1H2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.